Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Oragenics Q3 2026 Results: Net Loss of $2.6M, Loss Narrows

For the nine months ended September 30, 2026, Oragenics reported a net loss of $7.3 million, a slight improvement from the $7.6 million loss in the prior year period. The company's cash position decreased significantly to $2.2 million from $4.4 million at year-end 2025, primarily due to increased research and development spending on its lead product candidate, ONP-002.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-2.6-3.1
Net income-2.6-3.1
EPS (diluted, $ a share)$-0.58$-1.96

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: OGEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Oragenics Inc: key numbers

Share price
$0.1980Close, Nov 16
Market cap
$893K
Shares outstanding
4.51MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Oragenics Inc

All →
8:31 AM ET 8-K
Investor Presentation

Oragenics Investor Presentation

Oragenics, Inc. announced that its Chief Medical Officer, James P. Kelly, will deliver a presentation at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The presentation, titled 'Successful Case Studies', will be used during the forum and has been filed as a formal exhibit to the company's 8-K.

Counterparty
IPAC-RS 2026 Nasal Innovation Forum

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.